THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (UK MAR)

ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT

TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE

INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

and New York, NY, May 3, 2023 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the "Company"), an ophthalmology-focused

bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar

market, today announced that two presentations will be given on OK-101 at the American Society of Cataract and Refractive Surgery (ASCRS

2023) in in San Diego, CA, May 5-8, 2023.

Company is pleased that Pedram Hamrah, MD, Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology

at New England Eye Center at Tufts Medical Center, a leading expert on corneal neuropathic pain and DED, will be presenting both papers

at this ASCRS meeting in San Diego. These presentations will cover pre-clinical and animal model data on OK-101 in treating DED and Neuropathic

title: Ocular Surface Disease

Date: Saturday, May 6, 2023

time: 3:30 PM-5:00 PM

Title: OK-101, a Novel Chemerin Receptor Agonist, Decreased Clinical Signs and Symptoms and Improved Immune Tolerance in Dry Eye Mouse

title: Ocular Surface Disease II

Date: Sunday, May 7, 2023

time: 8:00 AM-9:30 AM

Title: OK-101, a Novel Chemerin Receptor Agonist, Improves Neuropathic Corneal Pain in Ciliary Nerve Ligation Mouse Model

is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells

of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce

a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing

activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of

the lipid anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the

Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange

plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For

further information, please visit www.okyopharma.com.

person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of